{"id":26684,"date":"2024-11-29T10:19:29","date_gmt":"2024-11-29T09:19:29","guid":{"rendered":"https:\/\/idibell.cat\/?p=26684"},"modified":"2024-11-29T10:19:29","modified_gmt":"2024-11-29T09:19:29","slug":"un-estudi-internacional-amb-participacio-de-lidibell-mostra-que-el-farmac-semaglutida-per-a-lobesitat-i-la-diabetis-protegeix-el-ronyo-en-persones-obeses-amb-malaltia-renal","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2024\/11\/un-estudi-internacional-amb-participacio-de-lidibell-mostra-que-el-farmac-semaglutida-per-a-lobesitat-i-la-diabetis-protegeix-el-ronyo-en-persones-obeses-amb-malaltia-renal\/","title":{"rendered":"Un estudi internacional amb participaci\u00f3 de l’IDIBELL mostra que el f\u00e0rmac semaglutida, per a l’obesitat i la diabetis, protegeix el rony\u00f3 en persones obeses amb malaltia renal"},"content":{"rendered":"

Un estudi multic\u00e8ntric internacional ha mostrat que el f\u00e0rmac Semaglutida, dissenyat per tractar diabetis i obesitat, protegeix el rony\u00f3 en pacients obesos amb malaltia renal cr\u00f2nica.<\/span>\u00a0<\/span><\/p>\n

En l’estudi SMART (<\/span>SeMaglutide and Albuminuria Reduction Trial in obese individuals without diabetis<\/span><\/i>), que s’ha realitzat en pacients no diab\u00e8tics amb malaltia renal i obesitat, han participat diversos centres de quatre pa\u00efsos (Espanya, que ha estat el m\u00e0xim reclutador, Holanda, Alemanya i Canad\u00e0), sota la coordinaci\u00f3 del Department de Farm\u00e0cia i Farmacologia Cl\u00ednica de la Universitat de Groningen (Pa\u00efsos Baixos).<\/span>\u00a0<\/span><\/p>\n

L’IDIBELL i l’Hospital Universitari de Bellvitge han participat en l’estudi amb el Dr. Josep Maria Cruzado, nefr\u00f2leg i cap del grup d’investigaci\u00f3 en nefrologia i trasplantament renal, a m\u00e9s de l’Institut d’Investigaci\u00f3 Sanit\u00e0ria INCLIVA de l’Hospital Cl\u00ednic Universitari de Val\u00e8ncia i la Universitat de Val\u00e8ncia, aix\u00ed com el Vall d’Hebron Institut d’Investigaci\u00f3 (VHIR) i l’Hospital Universitari Vall d’Hebron de Barcelona. Els nou resultats s’han presentat al Congr\u00e9s Kidney Week 2024, de la Societat Americana de Nefrologia, celebrat a San Diego (Estats Units) del 24 al 26 d’octubre i s’han publicat simult\u00e0niament a la prestigiosa revista <\/span>Nature Medicine<\/span><\/i>.<\/span>\u00a0<\/span><\/p>\n

Obesitat i malaltia renal cr\u00f2nica<\/span><\/b>\u00a0<\/span><\/p>\n

El sobrep\u00e8s i l’obesitat constitueixen en l’actualitat un problema de salut mundial. Es defineixen com a anormals o excessius quan l’acumulaci\u00f3 de greix suposa un risc. La prevalen\u00e7a de l’obesitat a tot el m\u00f3n s’ha triplicat des del 1975 i actualment afecta 650 milions d’adults (13%) i 340 milions de nens (18%). A Espanya, gaireb\u00e9 el 40% de la poblaci\u00f3 t\u00e9 sobrep\u00e8s i el 22%, obesitat. A m\u00e9s, 3 de cada 10 pacients amb malaltia renal cr\u00f2nica pateixen obesitat.<\/span>\u00a0<\/span><\/p>\n

En l’actualitat, m\u00e9s de 850 milions de persones al m\u00f3n pateixen algun tipus de malaltia renal. A Espanya el 15% de la poblaci\u00f3 adulta t\u00e9 malaltia renal. La mortalitat en pacients amb malaltia renal cr\u00f2nica ha augmentat un 30% en els \u00faltims anys a Espanya, provocant 10.700 morts el 2016.\u00a0<\/span>\u00a0<\/span><\/p>\n

Hi ha interacci\u00f3 entre l’obesitat i la malaltia renal cr\u00f2nica i els mecanismes fisiopatol\u00f2gics que subjauen a aquesta interacci\u00f3 s\u00f3n complexos. S’han utilitzat ter\u00e0pies amb f\u00e0rmacs antidiab\u00e8tics i d’altres per reduir el pes corporal en pacients amb i sense diabetis, sense induir hipogluc\u00e8mia. No obstant, el seu efecte espec\u00edfic en pacients amb malaltia renal cr\u00f2nica i obesos es desconeixia fins al moment.<\/span>\u00a0<\/span><\/p>\n

En l’actual estudi cl\u00ednic aleatoritzat, doble cec i controlat amb placebo han participat 125 pacients amb malaltia renal cr\u00f2nica i sense diabetis, a qui es va subministrar a l’atzar Semaglutida 2,4 mg per setmana o placebo.<\/span>\u00a0<\/span><\/p>\n

En l’estudi han participat, a m\u00e9s, altres centres espanyols, com l’Hospital Ribera-Polusa Lugo. Han intervingut, a m\u00e9s, altres centres dels Pa\u00efsos Baixos, Alemanya i Canad\u00e0.<\/span>\u00a0<\/span><\/p>\n

L’estudi va ser finan\u00e7at a trav\u00e9s d’una beca de recerca de Novo Nordisk a la Universitat M\u00e8dica Centre Groninger.<\/span><\/p>\n

 <\/p>\n

L\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l\u2019Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l\u2019Institut Catal\u00e0 de la Salut, l\u2019Institut Catal\u00e0 d\u2019Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d\u2019Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L\u2019any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Els nou resultats s’han presentat al Congr\u00e9s Kidney Week 2024, de la Societat Americana de Nefrologia, a San Diego, i s’han publicat simult\u00e0niament a la prestigiosa revista Nature Medicine. A Espanya, el 40% de la poblaci\u00f3 t\u00e9 sobrep\u00e8s, el 22% de la poblaci\u00f3 t\u00e9 obesitat i 3 de cada 10 pacients amb malaltia renal cr\u00f2nica pateixen obesitat.<\/p>\n","protected":false},"author":8,"featured_media":26685,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[334,339,479],"tags":[],"class_list":["post-26684","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-translacional","category-nefrologia-i-transplantament-renal","category-p-de-malalties-infeccioses-i-transplantaments"],"publishpress_future_action":{"enabled":false,"date":"2024-12-11 21:06:40","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=26684"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26684\/revisions"}],"predecessor-version":[{"id":26686,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26684\/revisions\/26686"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/26685"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=26684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=26684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=26684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}